PL378432A1 - Inhibitory p38 i sposoby ich zastosowania - Google Patents
Inhibitory p38 i sposoby ich zastosowaniaInfo
- Publication number
- PL378432A1 PL378432A1 PL378432A PL37843204A PL378432A1 PL 378432 A1 PL378432 A1 PL 378432A1 PL 378432 A PL378432 A PL 378432A PL 37843204 A PL37843204 A PL 37843204A PL 378432 A1 PL378432 A1 PL 378432A1
- Authority
- PL
- Poland
- Prior art keywords
- inhibitors
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/378,164 US7135575B2 (en) | 2003-03-03 | 2003-03-03 | P38 inhibitors and methods of use thereof |
US10/688,849 US20040180896A1 (en) | 2003-03-03 | 2003-10-15 | P38 inhibitors and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
PL378432A1 true PL378432A1 (pl) | 2006-04-03 |
PL214032B1 PL214032B1 (pl) | 2013-06-28 |
Family
ID=32965317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL378432A PL214032B1 (pl) | 2003-03-03 | 2004-02-25 | Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7521447B2 (pl) |
EP (1) | EP1606283B1 (pl) |
JP (1) | JP4617299B2 (pl) |
KR (1) | KR101099281B1 (pl) |
AU (1) | AU2004218463B2 (pl) |
CA (1) | CA2517517C (pl) |
IS (1) | IS2675B (pl) |
MX (1) | MXPA05009459A (pl) |
NO (1) | NO328913B1 (pl) |
PL (1) | PL214032B1 (pl) |
RU (1) | RU2357957C2 (pl) |
WO (1) | WO2004078116A2 (pl) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004037789A2 (en) * | 2002-10-24 | 2004-05-06 | Merck Patent Gmbh | Methylene urea derivatives as raf-kinase inhibitors |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
MXPA06002853A (es) * | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
RU2006121990A (ru) | 2003-11-21 | 2007-12-27 | Эррэй Биофарма Инк. (Us) | Ингибиторы протеинкиназ акт |
EP1720878A1 (en) | 2004-02-27 | 2006-11-15 | F.Hoffmann-La Roche Ag | Heteroaryl-fused pyrazolo derivatives |
AU2005273612B2 (en) * | 2004-08-12 | 2010-10-14 | Pfizer Inc. | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
EP1647549A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
MX2007005291A (es) * | 2004-11-02 | 2007-07-19 | Pfizer | Metodos para preparar compuestos de indazol. |
CA2586176A1 (en) * | 2004-11-02 | 2006-05-11 | Srinivasan Babu | Methods for preparing indazole compounds |
CN101052633A (zh) * | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
UA95907C2 (en) | 2005-05-02 | 2011-09-26 | Эррей Биофарма Инк. | Mitotic kinesin inhibitors and methods of use thereof |
EP1883404A4 (en) * | 2005-05-11 | 2010-03-31 | Array Biopharma Inc | P38 INHIBITORS AND METHODS OF USE |
CN101242832B (zh) | 2005-08-25 | 2011-08-10 | 霍夫曼-拉罗奇有限公司 | 用作p38 MAP激酶抑制剂的稠合吡唑 |
MX2008002588A (es) | 2005-08-25 | 2008-03-18 | Hoffmann La Roche | Inhibidores de p38-map-cinasa y los metodos para utilizarlos. |
BRPI0614884A2 (pt) * | 2005-08-25 | 2011-04-19 | Hoffmann La Roche | inibidores de p38 map cinase e métodos para uso dos mesmos |
US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
WO2007031977A2 (en) * | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors |
EP1934174B1 (en) * | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
EP1943226A2 (en) * | 2005-10-13 | 2008-07-16 | Smithkline Beecham Corporation | Phenol ethers as modulators of the opioid receptors |
JP2009515984A (ja) * | 2005-11-15 | 2009-04-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なアザインダゾール |
EP1970375A4 (en) * | 2005-11-29 | 2010-06-02 | Toray Industries | ARYLMETHYLENE UREE DERIVATIVE AND USE THEREOF |
EP1981851B1 (en) | 2006-01-31 | 2012-01-25 | Array Biopharma, Inc. | Kinase inhibitors and methods of use thereof |
JP2009531445A (ja) * | 2006-03-29 | 2009-09-03 | アレイ バイオファーマ、インコーポレイテッド | p38インヒビターおよびその使用方法 |
DK2068886T3 (da) * | 2006-10-03 | 2013-11-18 | Tekmira Pharmaceuticals Corp | Lipidholdige præparater |
TW200831085A (en) * | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
CA2671982C (en) * | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
WO2008076446A1 (en) * | 2006-12-18 | 2008-06-26 | Coleman Peter R | Accelerated opiate dependence detoxification process |
CA2672719A1 (en) * | 2006-12-19 | 2008-06-26 | F. Hoffmann-La Roche Ag | Pyrazolo [3, 4 -d] pyrimidine p38 map kinase inhibitors |
CA2673095C (en) * | 2006-12-20 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
US8202899B2 (en) * | 2007-07-25 | 2012-06-19 | Array Biopharma Inc. | Pyrazole urea derivatives used as kinase inhibitors |
EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
AU2009272900B2 (en) * | 2008-07-15 | 2012-04-19 | F. Hoffmann-La Roche Ag | Substituted indolyl and indazolyl derivatives and uses thereof |
KR20110070887A (ko) * | 2008-10-02 | 2011-06-24 | 레스피버트 리미티드 | P38 엠에이피 키나제 억제제 |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
KR20110094130A (ko) | 2008-12-11 | 2011-08-19 | 레스피버트 리미티드 | P38 map 키나제 억제제 |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
MX345155B (es) * | 2009-10-12 | 2017-01-18 | F Hoffmann-La Roche Ag * | Combinaciones de un inhibidor de pi3k y un inhibidor de mek. |
JP2013519685A (ja) | 2010-02-11 | 2013-05-30 | ヴァンダービルト ユニバーシティー | mGluR4アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 |
AR085908A1 (es) | 2011-03-16 | 2013-11-06 | Hoffmann La Roche | DERIVADOS DE 3-BUTIN-2-OL Y DE CARBONITRILO CON ACTIVIDAD INHIBIDORA DE LA QUINASA INDUCTORA DE NF-kB (NIK) |
CN103974953B (zh) * | 2011-12-09 | 2016-06-29 | 奇斯药制品公司 | 激酶抑制剂 |
PT2819998T (pt) * | 2012-03-01 | 2022-05-05 | Array Biopharma Inc | Formas cristalinas de cloridrato de 1-(3-terc-butil-1-ptolil- 1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1hindazol- 5-iloxi)benzil)ureia |
JP2015530378A (ja) * | 2012-08-29 | 2015-10-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 変形性関節症の処置のためのddr2インヒビター |
GEP201706690B (en) | 2012-10-12 | 2017-06-26 | Exelixis Inc | Novel process for making compounds for use in treatment of cancer |
EP2961744B1 (en) | 2013-02-27 | 2017-06-28 | Array Biopharma, Inc. | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof |
WO2014145485A2 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of Columbia University In The City Of New York | Map kinase modulators and uses thereof |
CA2927675A1 (en) * | 2013-10-18 | 2015-04-23 | Blanchette Rockefeller Neurosciences Institute | Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases |
CN104974160B (zh) * | 2014-04-08 | 2017-12-05 | 辰欣药业股份有限公司 | 2‑甲基吡唑并[1,5‑a]嘧啶‑6‑羧酸衍生物及其应用 |
JP6820854B2 (ja) * | 2015-01-18 | 2021-01-27 | エスアールアイ インターナショナルSRI International | Map4k4(hgk)インヒビター |
RU2675496C1 (ru) * | 2017-03-31 | 2018-12-20 | Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук | Способ получения алкиловых эфиров гидроксибензойных кислот |
CN108947879B (zh) * | 2017-05-17 | 2022-06-28 | 中国科学院上海药物研究所 | Prmt i型抑制剂及其制备方法和用途 |
LT3691620T (lt) | 2017-10-05 | 2022-09-26 | Fulcrum Therapeutics, Inc. | P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
AU2019242628A1 (en) | 2018-03-26 | 2020-09-24 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
US20220380316A1 (en) | 2019-10-28 | 2022-12-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of arry-797 and process for preparation thereof |
CN113354558B (zh) * | 2021-07-12 | 2022-03-11 | 无锡双启科技有限公司 | 一种2-氨基-5-氟苯腈的制备方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5998060A (ja) * | 1982-11-27 | 1984-06-06 | Fujisawa Pharmaceut Co Ltd | インダゾ−ル誘導体、その製造法および農薬 |
US4571255A (en) * | 1983-12-29 | 1986-02-18 | Ppg Industries, Inc. | Subsituted phenoxybenzisoxazole herbicides |
JPS6368568A (ja) * | 1986-09-10 | 1988-03-28 | Otsuka Pharmaceut Factory Inc | p−アミノフエノ−ル誘導体 |
NZ224714A (en) * | 1987-06-01 | 1990-03-27 | Janssen Pharmaceutica Nv | Substituted benzotriazole derivatives and pharmaceutical compositions |
IE910278A1 (en) * | 1990-02-16 | 1991-08-28 | Ici Plc | Heterocyclic compounds |
AU662997B2 (en) * | 1992-07-03 | 1995-09-21 | Ihara Chemical Industry Co. Ltd. | Condensed heterocyclic derivative and weedkiller |
CA2150326A1 (en) * | 1994-05-27 | 1995-11-28 | Kimihiro Murakami | Azolyl methyl phenyl derivatives having aromatase inhibitory activity |
EP0854870B1 (en) | 1995-10-06 | 2009-06-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
KR100568438B1 (ko) | 1997-04-24 | 2006-04-07 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 염증성 질환의 치료에 유용한 치환된 이미다졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
AU7726898A (en) | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO1999020624A1 (en) | 1997-10-20 | 1999-04-29 | F.Hoffmann-La Roche Ag | Bicyclic kinase inhibitors |
JP2001521934A (ja) | 1997-11-03 | 2001-11-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬としての芳香族ヘテロ環式化合物 |
GB9820767D0 (en) * | 1998-09-23 | 1998-11-18 | Cerebrus Ltd | Chemical compounds VIII |
MXPA01008440A (es) | 1999-02-22 | 2002-04-24 | Boehringer Ingelheim Pharma | Derivados heterociclicos policiclos como agentes anti-inflamatorios.. |
EP1165516B1 (en) | 1999-03-12 | 2004-10-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic urea and related compounds useful as anti-inflammatory agents |
WO2000055152A1 (en) | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
WO2000059930A1 (en) * | 1999-04-05 | 2000-10-12 | Merck & Co., Inc. | A method of treating cancer |
IL146309A0 (en) | 1999-05-21 | 2002-07-25 | Scios Inc | Indole-type derivatives as inhibitors of p38 kinase |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
WO2001038306A1 (en) | 1999-11-27 | 2001-05-31 | Dong Wha Pharm. Ind. Co., Ltd | Novel 3-nitropyridine derivatives and the pharmaceutical compositions containing said derivatives |
AU4890301A (en) * | 2000-04-17 | 2001-10-30 | Dong Wha Pharmaceutical Industrial Co., Ltd. | 6-methylnicotinamide derivatives as antiviral agents |
JP2004529859A (ja) | 2000-11-20 | 2004-09-30 | サイオス インコーポレイテッド | インドール誘導体とp38キナーゼの阻害剤としてのその使用方法 |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
MXPA03008144A (es) | 2001-03-09 | 2003-12-12 | Pfizer Prod Inc | Nuevos compuestos antiinflamatorios de triazolopiridinas. |
JPWO2002100833A1 (ja) | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Rhoキナーゼ阻害剤 |
JP2005506350A (ja) | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物 |
AU2002353186A1 (en) * | 2001-12-19 | 2003-06-30 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
AU2003221184A1 (en) * | 2002-03-29 | 2003-10-27 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for endothelial disorder |
JP4681451B2 (ja) * | 2002-10-28 | 2011-05-11 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Rho−キナーゼ阻害剤としてのヘテロアリールオキシ置換フェニルアミノピリミジン類 |
AU2003293376A1 (en) * | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
US20090048301A1 (en) * | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
AU2004312312A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Opioid receptor antagonists |
EP1883404A4 (en) * | 2005-05-11 | 2010-03-31 | Array Biopharma Inc | P38 INHIBITORS AND METHODS OF USE |
-
2004
- 2004-02-25 WO PCT/US2004/005693 patent/WO2004078116A2/en active Application Filing
- 2004-02-25 AU AU2004218463A patent/AU2004218463B2/en not_active Expired
- 2004-02-25 MX MXPA05009459A patent/MXPA05009459A/es active IP Right Grant
- 2004-02-25 CA CA2517517A patent/CA2517517C/en not_active Expired - Lifetime
- 2004-02-25 EP EP04714621A patent/EP1606283B1/en not_active Expired - Lifetime
- 2004-02-25 JP JP2006508838A patent/JP4617299B2/ja not_active Expired - Lifetime
- 2004-02-25 PL PL378432A patent/PL214032B1/pl unknown
- 2004-02-25 RU RU2005131197/04A patent/RU2357957C2/ru active
- 2004-02-25 US US10/788,044 patent/US7521447B2/en active Active
-
2005
- 2005-09-02 KR KR1020057016417A patent/KR101099281B1/ko active IP Right Grant
- 2005-09-21 IS IS8037A patent/IS2675B/is unknown
- 2005-09-26 NO NO20054453A patent/NO328913B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
PL214032B1 (pl) | 2013-06-28 |
MXPA05009459A (es) | 2006-05-17 |
IS2675B (is) | 2010-09-15 |
AU2004218463B2 (en) | 2009-07-16 |
NO328913B1 (no) | 2010-06-14 |
NO20054453D0 (no) | 2005-09-26 |
KR101099281B1 (ko) | 2011-12-26 |
JP4617299B2 (ja) | 2011-01-19 |
JP2006519259A (ja) | 2006-08-24 |
CA2517517A1 (en) | 2004-09-16 |
RU2357957C2 (ru) | 2009-06-10 |
WO2004078116A2 (en) | 2004-09-16 |
AU2004218463A1 (en) | 2004-09-16 |
EP1606283A2 (en) | 2005-12-21 |
RU2005131197A (ru) | 2006-05-10 |
EP1606283A4 (en) | 2007-05-23 |
KR20050106484A (ko) | 2005-11-09 |
US7521447B2 (en) | 2009-04-21 |
EP1606283B1 (en) | 2008-10-08 |
CA2517517C (en) | 2012-12-18 |
NO20054453L (no) | 2005-11-29 |
WO2004078116A9 (en) | 2008-09-12 |
US20040192653A1 (en) | 2004-09-30 |
IS8037A (is) | 2005-09-21 |
WO2004078116A3 (en) | 2004-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI346663B (en) | P38 inhibitors and methods of use thereof | |
PL378432A1 (pl) | Inhibitory p38 i sposoby ich zastosowania | |
AU2003303128A8 (en) | Inhibitors and methods of use thereof | |
HK1079789A1 (zh) | 血管靜態毒性試劑及其使用方法 | |
AU2003217870A8 (en) | Pini-modulating compounds and methods of use thereof | |
AU2003213673A8 (en) | Pin1-modulating compounds and methods of use thereof | |
IL173936A0 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
EP1606285A4 (en) | IDO INHIBITORS AND METHODS OF USE THEREOF | |
EP1507756A4 (en) | CCR9 INHIBITORS AND USE THEREOF | |
EP1465615A4 (en) | TRICYCLIC BISENONE DERIVATIVES AND METHODS OF USE | |
IL213843A0 (en) | 4-aminotetracyclines and methods of use thereof | |
AU2003259735A8 (en) | Small-mer compositions and methods of use | |
IL174431A0 (en) | Substituted benzazoles and use thereof as inhibitors of raf kinase | |
EP1691812A4 (en) | GTPASE INHIBITORS AND METHOD OF USE | |
EP1448218A4 (en) | BETA SECRETASE INHIBITORS AND METHODS OF USE | |
EP1639086A4 (en) | RNA INTERFERASES AND METHODS OF USE | |
ZA200601293B (en) | Proteasome inhibitors and methods of using the same | |
EP1789437A4 (en) | INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF | |
EP1476150A4 (en) | CARBOXY FULLERES AND USE METHOD THEREFOR | |
AU2003299441A8 (en) | Nf-hev compositions and methods of use | |
EP1663255A4 (en) | WITHANAMID AND WITHANOLID COMPOSITIONS AND APPLICATION METHOD THEREFOR | |
EP1633749A4 (en) | DEAZAFLAVIN COMPOUNDS AND METHODS OF USE | |
EP1883404A4 (en) | P38 INHIBITORS AND METHODS OF USE | |
AU2003210983A8 (en) | Kinase inhibitors and methods of use thereof | |
EP1682115A4 (en) | HIF-1 HEMMER AND APPLICATION METHOD THEREFOR |